

Translation

## PATENT COOPERATION TREATY

## PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY  
(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>J 7185/cm</b>	FOR FURTHER ACTION		See Form PCT/IPEA/416																
International application No <b>PCT/EP2004/005831</b>	International filing date (day/month/year) <b>28.05.2004</b>	Priority date (day/month/year) <b>18.06.2003</b>																	
International Patent Classification (IPC) or national classification and IPC																			
Applicant <b>IET GmbH</b>																			
<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <b>11</b> sheets, including this cover sheet.</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p>a. <input type="checkbox"/> (<i>sent to the applicant and to the International Bureau</i>) a total of _____ sheets, as follows:  <input type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).  <input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.</p> <p>b. <input type="checkbox"/> (<i>sent to the International Bureau only</i>) a total of (indicate type and number of electronic carrier(s)) _____ containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>																			
<p>4. This report contains indications relating to the following items:</p> <table> <tbody> <tr><td><input checked="" type="checkbox"/></td><td>Box No. I Basis of the report</td></tr> <tr><td><input type="checkbox"/></td><td>Box No. II Priority</td></tr> <tr><td><input checked="" type="checkbox"/></td><td>Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td></tr> <tr><td><input type="checkbox"/></td><td>Box No. IV Lack of unity of invention</td></tr> <tr><td><input checked="" type="checkbox"/></td><td>Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td></tr> <tr><td><input type="checkbox"/></td><td>Box No. VI Certain documents cited</td></tr> <tr><td><input checked="" type="checkbox"/></td><td>Box No. VII Certain defects in the international application</td></tr> <tr><td><input checked="" type="checkbox"/></td><td>Box No. VIII Certain observations on the international application</td></tr> </tbody> </table>				<input checked="" type="checkbox"/>	Box No. I Basis of the report	<input type="checkbox"/>	Box No. II Priority	<input checked="" type="checkbox"/>	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	<input type="checkbox"/>	Box No. IV Lack of unity of invention	<input checked="" type="checkbox"/>	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	<input type="checkbox"/>	Box No. VI Certain documents cited	<input checked="" type="checkbox"/>	Box No. VII Certain defects in the international application	<input checked="" type="checkbox"/>	Box No. VIII Certain observations on the international application
<input checked="" type="checkbox"/>	Box No. I Basis of the report																		
<input type="checkbox"/>	Box No. II Priority																		
<input checked="" type="checkbox"/>	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																		
<input type="checkbox"/>	Box No. IV Lack of unity of invention																		
<input checked="" type="checkbox"/>	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																		
<input type="checkbox"/>	Box No. VI Certain documents cited																		
<input checked="" type="checkbox"/>	Box No. VII Certain defects in the international application																		
<input checked="" type="checkbox"/>	Box No. VIII Certain observations on the international application																		
Date of submission of the demand	Date of completion of this report																		
Name and mailing address of the IPEA/EP	Authorized officer																		
Facsimile No.	Telephone No.																		

Form PCT/IPEA/409 (cover sheet) (January 2004)

BEST AVAILABLE COPY

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.  
PCT/EP2004/005831

Box No. 1	Basis of the report
<p>1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.</p> <p><input type="checkbox"/> This report is based on translations from the original language into the following language _____ which is the language of a translation furnished for the purposes of:</p> <p><input type="checkbox"/> international search (Rule 12.3 and 23.1(b))  <input type="checkbox"/> publication of the international application (Rule 12.4)  <input type="checkbox"/> international preliminary examination (Rule 55.2 and/or 55.3)</p> <p>2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):</p> <p><input type="checkbox"/> the international application as originally filed/furnished  <input checked="" type="checkbox"/> the description:      pages 1-36 _____ as originally filed/furnished      pages* _____ received by this Authority on _____      pages* _____ received by this Authority on _____</p> <p><input checked="" type="checkbox"/> the claims:      nos. 1-40 _____ as originally filed/furnished      nos.* _____ as amended (together with any statement) under Article 19      nos.* _____ received by this Authority on _____      nos.* _____ received by this Authority on _____</p> <p><input type="checkbox"/> the drawings:      sheets _____ as originally filed/furnished      sheets* _____ received by this Authority on _____      sheets* _____ received by this Authority on _____</p> <p><input checked="" type="checkbox"/> a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.</p> <p>3. <input type="checkbox"/> The amendments have resulted in the cancellation of:</p> <p><input type="checkbox"/> the description, pages _____  <input type="checkbox"/> the claims, nos. _____  <input type="checkbox"/> the drawings, sheets/figs _____  <input type="checkbox"/> the sequence listing (specify): _____  <input type="checkbox"/> any table(s) related to sequence listing (specify): _____</p> <p>4. <input type="checkbox"/> This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).</p> <p><input type="checkbox"/> the description, pages _____  <input type="checkbox"/> the claims, nos. _____  <input type="checkbox"/> the drawings, sheets/figs _____  <input type="checkbox"/> the sequence listing (specify): _____  <input type="checkbox"/> any table(s) related to sequence listing (specify): _____</p>	

\* If item 4 applies, some or all of those sheets may be marked "superseded."

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/EP2004/005831

## Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

the entire international application  
 claims Nos. 6, 7 and 16-19; claim 15 in part

because:

the said international application, or the said claims Nos. \_\_\_\_\_ relate to the following subject matter which does not require an international preliminary examination (specify):

the description, claims or drawings (indicate particular elements below) or said claims Nos. \_\_\_\_\_ are so unclear that no meaningful opinion could be formed (specify):

the claims, or said claims Nos. \_\_\_\_\_ are so inadequately supported by the description that no meaningful opinion could be formed.  
 no international search report has been established for said claims Nos. 6, 7 and 16-19; claim 15 in part  
 the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:  
 the written form                             has not been furnished  
     does not comply with the standard  
 the computer readable form               has not been furnished  
     does not comply with the standard  
 the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.  
 See Supplemental Box for further details.

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/EP2004/005831

Box No. V		Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																						
<p><b>I. Statement</b></p> <table> <tr> <td rowspan="2">Novelty (N)</td> <td>Claims</td> <td>3-5, 8-14</td> <td>YES</td> </tr> <tr> <td>Claims</td> <td>1, 2, 15, 20-40</td> <td>NO</td> </tr> <tr> <td rowspan="2">Inventive step (IS)</td> <td>Claims</td> <td>3-5, 8, 9</td> <td>YES</td> </tr> <tr> <td>Claims</td> <td>1, 2, 10-15, 20-40</td> <td>NO</td> </tr> <tr> <td rowspan="2">Industrial applicability (IA)</td> <td>Claims</td> <td>1-5, 8-15, 20-40</td> <td>YES</td> </tr> <tr> <td>Claims</td> <td></td> <td>NO</td> </tr> </table>				Novelty (N)	Claims	3-5, 8-14	YES	Claims	1, 2, 15, 20-40	NO	Inventive step (IS)	Claims	3-5, 8, 9	YES	Claims	1, 2, 10-15, 20-40	NO	Industrial applicability (IA)	Claims	1-5, 8-15, 20-40	YES	Claims		NO
Novelty (N)	Claims	3-5, 8-14	YES																					
	Claims	1, 2, 15, 20-40	NO																					
Inventive step (IS)	Claims	3-5, 8, 9	YES																					
	Claims	1, 2, 10-15, 20-40	NO																					
Industrial applicability (IA)	Claims	1-5, 8-15, 20-40	YES																					
	Claims		NO																					
<p><b>2. Citations and explanations (Rule 70.7)</b></p> <p><b>Prior art documents</b></p> <p>In this written opinion the abbreviations D1 to D7 are used to refer to the searched prior art documents in the order in which they are listed in the international search report (ISR). The ISR was established by the Examining Authority.</p>																								
<p><b>1. <u>Summary of the application</u></b></p> <p>The application relates essentially to an NADH-dependent S-specific oxidoreductase with an amino acid sequence as defined by SEQ ID No. 9.</p>																								
<p><b>2. <u>Novelty (PCT Article 33(2))</u></b></p> <p>2.1 The subject matter of <u>claims 3 to 5 and 8 to 14</u> has not been made accessible to the public by the available prior art and can therefore be considered novel.</p> <p>2.2 The subject matter of <u>claims 1, 2, 15 and 20 to 40</u> fails to meet the requirements of PCT Article 33(2) and (3).</p>																								

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/EP2004/005831

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<p>2.3 Documents D1 (WO 93/18138), D2 (WO 02/086126), D3 (Jones et al.), D4 (Xie et al.), D5 (Schütte et al.), D6 (Cannio et al.) and D7 (Bayer et al.) all disclose NAD-dependent S-specific carbonyl reductases (see also page 1, line 20 to page 2, line 2 in the present application). In their present form <u>claims 1 and 2</u> are therefore inadmissible under EPC Article 54.</p> <p>2.4 The applicant is reminded that it is not permissible to use the origin of a sequence (human, mouse or, as in <u>claim 2</u>, "yeasts of the genus <i>Pichia</i> or <i>Candida</i>") to establish novelty over known sequences with the same structural features and the same activity. To a person skilled in the art it is not obvious, for example, whether a given NADH-dependent S-specific oxidoreductase is from <i>Pichia capsulata</i>, <i>Candida parapsilosis</i> or <i>Rhodococcus erythropolis</i>.</p> <p>2.5 Any known nucleotide sequence that encodes an NADH-dependent S-specific oxidoreductase is prejudicial to the novelty of the subject matter of <u>claim 15 (b)</u>. These known polynucleotides all hybridise with the sequences specified in claim 15 (a). It is noted that the term "strict [conditions]" is relative. Consequently the subject matter of <u>claims 20 to 22</u> cannot be considered novel at this point in time.</p> <p>2.6 The methods of <u>claims 23 to 40</u> are indistinguishable from the methods described in D1 (WO 93/18138) and D2 (WO 02/086126). The subject matter of these claims cannot therefore be considered novel.</p>	

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY		International application No. PCT/EP2004/005831
Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	
	<b>3. Inventive step (PCT Article 33(3))</b>	
	<p>3.1 The subject matter of <u>claims 3 to 5, 8 and 9</u> is not obvious from the available prior art and therefore meets the requirement of PCT Article 33(3).</p> <p>3.2 The subject matter of <u>claims 10 to 14</u> fails to meet the requirement of PCT Article 33(3).</p> <p>3.3 The subject matter of <u>claims 10 to 12</u> ("fragments") contributes nothing to the inventive solution to the problem addressed by the invention (i.e. that of providing a new oxidoreductase with high enantioselectivity (<i>S</i>-specific) and a high degree of stability against organic solvents (see page 3, lines 25 to 27)). The problem addressed by the invention is not solved by the subject matter of <u>claims 10 to 12</u>.</p> <p>3.4 The same argument applies to <u>claims 13 and 14</u>, which relate to an oxidoreductase as defined by SEQ ID No. 10. The sequence according to SEQ ID No. 10 is the sequence not of an oxidoreductase but rather of a 12-amino-acid-long fragment of an oxidoreductase that does not perform the specified function (see also page 4, lines 18 to 23).</p>	
	<b>4. Industrial applicability (PCT Article 33(4))</b>	
	<u>Claims 1 to 5, 8 to 15 and 20 to 40</u> all meet the requirement of PCT Article 33(4).	

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/EP2004/005831

## Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

The application as a whole lacks conciseness on account of the large number of independent claims (PCT Rule 6.1(a)).

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/EP2004/005831

## Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claim 1 defines oxidoreductases which reduce a carbonyl compound to the corresponding (*S*)-hydroxy compound. The activity measurement in dependent claim 4 is not consistent with this because the product is an (*R*)-hydroxy compound, not an (*S*)-hydroxy compound as in claim 1.

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.  
PCT/EP2004/005831

## Supplemental Box Relating to Sequence Listing

## Continuation of Box No. I, item 2:

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention this report was established on the basis of:
  - a. type of material
 

a sequence listing  
 table(s) related to the sequence listing
  - b. format of material
 

in written format  
 in computer readable form
  - c. time of filing/furnishing
 

contained in the international application as filed  
 filed together with the international application in computer readable form  
 furnished subsequently to this Authority for the purposes of search and/or examination  
 received by this Authority as an amendment\* on \_\_\_\_\_
2.  In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished

## 3. Additional comments:

The original application includes 5 pages of sequence listing (10 sequences) (pages 1 to 5 of the description).

\* If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked "superseded."

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.  
PCT/EP2004/005831

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.  
Continuation of:

Box IIINon-establishment of opinion with regard to novelty,  
inventive step and industrial applicability

1. No international search report was established in respect of the subject matter of claims 6, 7 and 16 to 19, or in respect of claim 15 (in part). The subject matter not covered by the search report will therefore not be dealt with in the international preliminary examination (PCT Rule 66.1(e)).
2. Claim 6 covers all oxidoreductases that are characterised by "70% or 80% identical amino acids to the amino acid sequence of SEQ ID No. 9", and further characterised in that they have 1 to 40 amino acids more or 1 to 40 amino acids less. Firstly it is completely unclear which sequences are covered by this claim (PCT Article 6), and secondly there is only a limited number of such oxidoreductases that are fully disclosed (PCT Article 5) and supported by the description (PCT Article 6). It is therefore not possible to carry out a meaningful search and examination in respect of this claim. The same applies to claim 7.
3. Claim 15 (c) relates to a polynucleotide which differs from the polynucleotides of claim 15 (a) and claim 15 (b) on account of the degeneration of the genetic code of the polynucleotides. The

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/EP2004/005831

## Supplemental Box

reference to the degeneration of the genetic code only makes sense if the protein which the polynucleotide is supposed to encode is defined by its exact amino acid sequence. This is not the case in claim 15 (a) or claim 15 (b) (no amino acid sequence is specified; use of the term "hybridises"). It is therefore not possible to carry out a meaningful search and examination in respect of the subject matter of claim 15 (c) (PCT Article 6).

4. Claim 16 seeks to define the DNA sequence in terms of an enzyme, but the amino acid sequence of the enzyme is not defined in the claim and it is completely unclear what the DNA sequences are. The phrase "70% ..." makes the claim even more unclear. It is therefore not possible to carry out a meaningful search and examination in respect of the subject matter of claims 16 and 17 (PCT Article 6).
5. It is completely unclear what DNA sequences are defined in claim 18 ("one or more parts"). It is therefore not possible to carry out a meaningful search and examination in respect of the subject matter of claims 18 and 19 (PCT Article 6).

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**